LMNL 6511
Alternative Names: LMNL-6511Latest Information Update: 29 Oct 2025
At a glance
- Originator Liminal BioSciences
 - Class Anti-inflammatories; Antifibrotics; Small molecules
 - Mechanism of Action GPR84 protein antagonists
 
- 
          
            
              Orphan Drug Status
              No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
 - New Molecular Entity Yes
 - Available For Licensing Yes
 
Highest Development Phases
- Phase I/II Fibrosis
 - Preclinical Inflammation
 
Most Recent Events
- 16 Oct 2025 Phase-I/II clinical trials in Fibrosis (In volunteers) in Canada (unspecified route) (Liminal Biosciences pipeline, October 2025)
 - 02 Jun 2023 Liminal BioSciences anticipates for CTA filling approval to conduct a phase I first-in-human clinical trial in healthy subjects in China in the second half of 2023
 - 02 Jun 2023 Pharmacodynamics data from a preclinical trial in Inflammation released by Liminal Biosciences